Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Paroxysmal or chronic atrial fibrillation (AF) develops in about 20- 25% of adult patients
with hypertrophic cardiomyopathy (HCM) and represents an important complication in the
clinical course of the disease, with adverse long-term consequences on functional status and
outcome.
Therefore, aggressive therapeutic strategies are indicated to restore and maintain sinus
rhythm (SR) in patients with HCM. Nevertheless, pharmacologic prevention of AF recurrence is
challenging because of the limited long-term efficacy and potentially hazardous side effects
of available treatment options. Currently radiofrequency catheter ablation (RFCA) of AF is
successfully used in clinical practice. However, comparison of the efficacy and safety of
these two therapeutic options has not been done up till now in randomized manner in this
group of patients.
Thus, the aim of the present study is to compare the efficacy and safety of RFCA vs.
antiarrhythmic drug therapy in patients with HCM and AF.